Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacyclics Plans Xcytrin NDA Based On New Data Analysis

This article was originally published in The Pink Sheet Daily

Executive Summary

Overall Phase III results for motexafin in brain metastases failed to meet endpoints but additional analyses found positive results from U.S. trial group.

You may also be interested in...



Pharmacyclics Gets “Refuse To File” Letter On Xcytrin

Company had hoped for priority review when it submitted its NDA for treatment of brain metastases from non-small cell lung cancer in December.

Pharmacyclics Eyes Priority Review For NSCLC Treatment

CEO tells “The Pink Sheet” DAILY of the firm’s plan for detailing and ex-U.S. commercialization.

Pharmacyclics Eyes Priority Review For NSCLC Treatment

CEO tells “The Pink Sheet” DAILY of the firm’s plan for detailing and ex-U.S. commercialization.

Topics

UsernamePublicRestriction

Register

PS064291

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel